Leukemia, acute lymphocytic, susceptibility to, 1

This Phase 2 trial tests a combination of two drugs—blinatumomab (given as a shot under the skin) and olverembatinib (a pill)—in 60 adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). The goal is to see if this combo can control the disease safely. Pa…

This study tests a new way to treat a fast-growing blood cancer called BCR-ABL positive B-cell acute lymphoblastic leukemia. About 80 adults will receive two drugs: ponatinib pills and blinatumomab injections under the skin. The goal is to see if this combination can control the …

This phase 2 trial is testing a new way to treat adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph-negative B-ALL). Instead of standard high-dose chemotherapy, patients receive a mix of low-dose chemo plus several targeted drugs (inotuzumab ozogamici…

This early-stage trial tests a new drug called LP-118 alongside standard treatments for adults newly diagnosed with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). The study will enroll 26 people to find the safest dose and see if the combination helps control the d…

This phase 2 trial tests whether combining olverembatinib (a targeted pill) with inotuzumab ozogamicin (an antibody-drug conjugate) can clear remaining leukemia cells in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who still have detectable …

This study reviews medical records of 103 adults with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who received ponatinib as their first treatment in regular care. Researchers want to see how many patients achieve a complete molecular response (undetectable leukem…